Challenges and progress in the development of a serogroup B meningococcal vaccine

被引：2

作者：

Lewis, Susan ^{[1
]}

Sadarangani, Manish ^{[1
]}

Hoe, J. Claire ^{[1
]}

Pollard, Andrew J. ^{[1
]}

机构：

[1] Univ Oxford, Churchill Hosp, Ctr Clin Vaccinol & Trop Med, Dept Paediat,Oxford Vaccine Grp, Oxford OX3 7LJ, England

来源：

EXPERT REVIEW OF VACCINES | 2009年 / 8卷 / 06期

关键词：

5CVMB; meningococcal disease; outer membrane protein; outer membrane vesicle vaccine; serogroup B; MEMBRANE-VESICLE VACCINE; INNER-CORE LIPOPOLYSACCHARIDE; MENINGITIDIS GROUP-B; H-BINDING PROTEIN; SYNERGISTIC BACTERICIDAL ACTIVITY; NEISSERIA-LACTAMICA PROTECTS; HUMAN-ANTIBODY RESPONSES; HUMAN SERUM ANTIBODIES; NEW-ZEALAND; ESCHERICHIA-COLI;

D O I：

10.1586/ERV.09.30

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Serogroup B meningococci cause the majority of the meningococcal disease burden in developed countries. Production of an effective and safe vaccine for serogroup B organisms has been hampered by the poor immunogenicity of the capsular polysaccharide that defines this group of bacteria. Previous efforts have focused on outer membrane vesicle vaccines, which have been implemented successfully during clonal outbreaks. However, the search for a universal vaccine against endemic polyclonal serogroup B meningococcal disease continues. In this review, we have highlighted recent development of outer membrane vesicle vaccines and progress in the evaluation of recombinant outer membrane protein vaccines.

引用

页码：729 / 745

页数：17

共 50 条

[21] The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology
Vanessa N Racloz
Silva JD Luiz
BMC Infectious Diseases, 10
[22] A review of the immunogenicity, safety and current recommendations for the meningococcal serogroup B vaccine, MenB-FHbp
Burman, Cynthia
Alderfer, Justine
Snow, Vincenza T.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2020, 45 (02) : 270 - 281
[23] Understanding Factors Affecting University A Students' Decision to Receive an Unlicensed Serogroup B Meningococcal Vaccine
Breakwell, Lucy
Vogt, Tara M.
Fleming, Debbie
Ferris, Mary
Briere, Elizabeth
Cohn, Amanda
Liang, Jennifer L.
JOURNAL OF ADOLESCENT HEALTH, 2016, 59 (04) : 457 - 464
[24] Emergence of serogroup X meningococcal disease in Africa: Need for a vaccine
Xie, Ouli
Pollard, Andrew J.
Mueller, Judith E.
Norheim, Gunnstein
VACCINE, 2013, 31 (27) : 2852 - 2861
[25] The bivalent factor H binding protein meningococcal serogroup B vaccine elicits bactericidal antibodies against representative non-serogroup B meningococci
Harris, Shannon L.
Tan, Cuiwen
Andrew, Lubomira
Hao, Li
Liberator, Paul A.
Absalon, Judith
Anderson, Annaliesa S.
Jones, Thomas R.
VACCINE, 2018, 36 (45) : 6867 - 6874
[26] Economic evaluation of meningococcal serogroup B (MenB) vaccines: A systematic review
Nwogu, Ifechukwu B.
Jones, Matthew
Langley, Tessa
VACCINE, 2021, 39 (16) : 2201 - 2213
[27] Young Adult and Parent Willingness to Pay for Meningococcal Serogroup B Vaccination
Huang, Liping
Srivastava, Amit
Fairchild, Angelyn
Whittington, Dale
Johnson, Reed
MDM POLICY & PRACTICE, 2024, 9 (02)
[28] Serogroup B meningococcal disease during Hajj: Preparing for the worst scenario
Khalil, Mohamed K. M.
Borrow, Ray
TRAVEL MEDICINE AND INFECTIOUS DISEASE, 2009, 7 (04) : 231 - 234
[29] The difficult road to new vaccines for pertussis and serogroup B meningococcal disease
Gorringe, Andrew R.
JOURNAL OF CHEMICAL TECHNOLOGY AND BIOTECHNOLOGY, 2016, 91 (01) : 9 - 15
[30] FetA Antibodies Induced by an Outer Membrane Vesicle Vaccine Derived from a Serogroup B Meningococcal Isolate with Constitutive FetA Expression
Sanders, Holly
Norheim, Gunnstein
Chan, Hannah
Dold, Christina
Vipond, Caroline
Derrick, Jeremy P.
Pollard, Andrew J.
Maiden, Martin C. J.
Feavers, Ian M.
PLOS ONE, 2015, 10 (10):

← 1 2 3 4 5 →